| Item Type | Name |
|
Concept
|
Antipsychotic Agents
|
|
Academic Article
|
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
|
|
Academic Article
|
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.
|
|
Academic Article
|
Risk of cardiovascular disease and sudden death in schizophrenia.
|
|
Academic Article
|
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
|
|
Academic Article
|
Bl-1020, a new ?-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
|
|
Academic Article
|
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
|
|
Academic Article
|
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
|
|
Academic Article
|
Limitations of controlled augmentation trials in schizophrenia.
|
|
Academic Article
|
Premorbid functioning and treatment response in recent-onset schizophrenia.
|
|
Academic Article
|
Body mass index and future schizophrenia in Israeli male adolescents.
|
|
Academic Article
|
Perceived patient threat and neuroleptic dosage.
|
|
Academic Article
|
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
|
|
Academic Article
|
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
|
|
Academic Article
|
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
|
|
Academic Article
|
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
|
|
Academic Article
|
Predictors of response to neuroleptic treatment in schizophrenia.
|
|
Academic Article
|
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
|
|
Academic Article
|
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.
|
|
Academic Article
|
Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
|
|
Academic Article
|
Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
|
|
Academic Article
|
Dopamine in schizophrenia: a review and reconceptualization.
|
|
Academic Article
|
Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients.
|
|
Academic Article
|
Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
|
|
Academic Article
|
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
|
|
Academic Article
|
Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia.
|
|
Academic Article
|
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
|
|
Academic Article
|
Effect of concurrent distraction on communication failures in schizophrenic patients. II. Medication status correlations.
|
|
Academic Article
|
Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites.
|
|
Academic Article
|
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
|
|
Academic Article
|
Long-term safety of risperidone.
|
|
Academic Article
|
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
|
|
Academic Article
|
Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study.
|
|
Academic Article
|
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance.
|
|
Academic Article
|
Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST).
|
|
Academic Article
|
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
|
|
Academic Article
|
The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial.
|
|
Academic Article
|
Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial.
|
|
Academic Article
|
Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial.
|
|
Academic Article
|
The brief negative symptom scale (BNSS): Sensitivity to treatment effects.
|